#POS0190 #EULAR2022 Disappointing news. Despite +ve Phase 2 RCT, Results from Phase 3 RCTs of Baricitinib in #lupus is inconclusive 💠SRI4 was met in BRAVE1 but not BRAVE2 despite identical study 💠BILAG MSK & Skin improved in BRAVE1 only BICLA wasn’t reported @RheumNow https://t.co/IfJRYEwFY8